TARIS, founded in 2008, is paving the way in the realm of biotechnology with its compelling vision captured by its slogan: "Innovative therapies for challenging bladder conditions, with a tailored, extended-release system and minimally-invasive procedures." Specializing in the healthcare, health and wellness, and pharmaceutical industries, TARIS Biomedical focuses on creating robust treatments for difficult-to-manage bladder diseases.
The company's unique system enables continuous drug delivery directly in the bladder for extended periods—ranging from weeks to even months—empowering tailored solutions for each condition through minimally-invasive, in-office procedures.
The last significant financial boost occurred with a $25.00M Series B investment on December 21, 2017, backed by a diverse group of investors, including Polaris Partners, RA Capital Management, Flagship Pioneering, Yonghua, Millhouse, Roman Abramovich, and Bristol-Myers Squibb, highlighting the strong market confidence in TARIS's cutting-edge therapeutics.
